Inactive Instrument

Hansa Biopharma AB Stock price Nasdaq Stockholm

Equities

SE0002148817

Biotechnology & Medical Research

Sales 2024 * 265M 24.81M Sales 2025 * 402M 37.68M Capitalization 1.53B 144M
Net income 2024 * -627M -58.7M Net income 2025 * -576M -53.93M EV / Sales 2024 * 8.63 x
Net Debt 2024 * 753M 70.48M Net Debt 2025 * 956M 89.52M EV / Sales 2025 * 6.18 x
P/E ratio 2024 *
-2.81 x
P/E ratio 2025 *
-3.43 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 18-03-19
Chief Tech/Sci/R&D Officer 53 Nov. 30
Chief Tech/Sci/R&D Officer 66 20-05-28
Members of the board TitleAgeSince
Director/Board Member 73 18-05-28
Chairman 61 22-06-29
Director/Board Member 59 19-05-21
More insiders
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company's operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS's goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company's patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
  1. Stock
  2. Equities
  3. Stock Hansa Biopharma AB
  4. Stock Hansa Biopharma AB - Nasdaq Stockholm